132 related articles for article (PubMed ID: 31525573)
21. Quantification of the HIV-integrase inhibitor raltegravir and detection of its main metabolite in human plasma, dried blood spots and peripheral blood mononuclear cell lysate by means of high-performance liquid chromatography tandem mass spectrometry.
Ter Heine R; Hillebrand MJ; Rosing H; van Gorp EC; Mulder JW; Beijnen JH; Huitema AD
J Pharm Biomed Anal; 2009 Feb; 49(2):451-8. PubMed ID: 19128911
[TBL] [Abstract][Full Text] [Related]
22. Intrapatient and interpatient pharmacokinetic variability of raltegravir in the clinical setting.
Siccardi M; DʼAvolio A; Rodriguez-Novoa S; Cuenca L; Simiele M; Baietto L; Calcagno A; Moss D; Bonora S; Soriano V; Back DJ; Owen A; Di Perri G
Ther Drug Monit; 2012 Apr; 34(2):232-5. PubMed ID: 22406652
[TBL] [Abstract][Full Text] [Related]
23. Pharmacokinetics of Raltegravir in HIV-Infected Patients on Rifampicin-Based Antitubercular Therapy.
Taburet AM; Sauvageon H; Grinsztejn B; Assuied A; Veloso V; Pilotto JH; De Castro N; Grondin C; Fagard C; Molina JM
Clin Infect Dis; 2015 Oct; 61(8):1328-35. PubMed ID: 26105170
[TBL] [Abstract][Full Text] [Related]
24. Raltegravir pharmacokinetics during pregnancy.
Watts DH; Stek A; Best BM; Wang J; Capparelli EV; Cressey TR; Aweeka F; Lizak P; Kreitchmann R; Burchett SK; Shapiro DE; Hawkins E; Smith E; Mirochnick M;
J Acquir Immune Defic Syndr; 2014 Dec; 67(4):375-81. PubMed ID: 25162818
[TBL] [Abstract][Full Text] [Related]
25. Atazanavir increases the plasma concentrations of 1200 mg raltegravir dose.
Krishna R; East L; Larson P; Valiathan C; Deschamps K; Luk JA; Bethel-Brown C; Manthos H; Brejda J; Gartner M
Biopharm Drug Dispos; 2016 Dec; 37(9):533-541. PubMed ID: 27696440
[TBL] [Abstract][Full Text] [Related]
26. Potential role of raltegravir-based therapy to induce rapid viral decay in highly viraemic HIV-infected neonates.
Ripamonti D; Tatarelli P; Mangili G; Gotta C; Benatti SV; Bruzzone B; Callegaro A; Viscoli C; Ruggeri M; Di Biagio A
J Chemother; 2016 Aug; 28(4):337-40. PubMed ID: 25248795
[TBL] [Abstract][Full Text] [Related]
27. A conventional LC-MS method developed for the determination of plasma raltegravir concentrations.
Takahashi M; Konishi M; Kudaka Y; Okumura N; Hirano A; Terahata N; Banno K; Kaneda T
Biol Pharm Bull; 2008 Aug; 31(8):1601-4. PubMed ID: 18670096
[TBL] [Abstract][Full Text] [Related]
28. A safety evaluation of raltegravir for the treatment of HIV.
de Miguel R; Montejano R; Stella-Ascariz N; Arribas JR
Expert Opin Drug Saf; 2018 Feb; 17(2):217-223. PubMed ID: 29199485
[TBL] [Abstract][Full Text] [Related]
29. One-month transplacental pharmacokinetics of raltegravir in a premature newborn after short-course treatment of the HIV-1-infected mother.
Clavel-Osorio C; Cazassus F; Stegmann S; Huc-Anaïs P; Lecam D; Peytavin G
Antimicrob Agents Chemother; 2013 Dec; 57(12):6393-4. PubMed ID: 24080650
[TBL] [Abstract][Full Text] [Related]
30. Safety and efficacy at 240 weeks of different raltegravir formulations in children with HIV-1: a phase 1/2 open label, non-randomised, multicentre trial.
Nachman S; Alvero C; Teppler H; Homony B; Rodgers AJ; Graham BL; Fenton T; Frenkel LM; Browning RS; Hazra R; Wiznia AA;
Lancet HIV; 2018 Dec; 5(12):e715-e722. PubMed ID: 30527329
[TBL] [Abstract][Full Text] [Related]
31. [Pharmacokinetics and interactions of raltegravir].
Placeres Alsina MM; Tuset Creus M; Miró JM
Enferm Infecc Microbiol Clin; 2008 Nov; 26 Suppl 12():23-8. PubMed ID: 19572422
[TBL] [Abstract][Full Text] [Related]
32. Maternal-Neonatal Raltegravir Population Pharmacokinetics Modeling: Implications for Initial Neonatal Dosing.
Lommerse J; Clarke D; Kerbusch T; Merdjan H; Witjes H; Teppler H; Mirochnick M; Acosta EP; Wenning L; Nachman S; Chain A
CPT Pharmacometrics Syst Pharmacol; 2019 Sep; 8(9):643-653. PubMed ID: 31215170
[TBL] [Abstract][Full Text] [Related]
33. Determination of furosemide and its glucuronide metabolite in plasma, plasma ultrafiltrate and urine by HPLC-MS/MS with application to secretion and metabolite formation clearances in non-pregnant and pregnant women.
Benzi JRL; Rocha A; Colombari JC; Pego AMG; Dos Santos Melli PP; Duarte G; Lanchote VL
J Pharm Biomed Anal; 2023 Oct; 235():115635. PubMed ID: 37634358
[TBL] [Abstract][Full Text] [Related]
34. Effect of metal-cation antacids on the pharmacokinetics of 1200 mg raltegravir.
Krishna R; East L; Larson P; Valiathan C; Butterfield K; Teng Y; Hernandez-Illas M
J Pharm Pharmacol; 2016 Nov; 68(11):1359-1365. PubMed ID: 27671833
[TBL] [Abstract][Full Text] [Related]
35. The pharmacokinetic profile of raltegravir-containing antiretroviral therapy in HIV-infected individuals over 60 years of age.
Vera JH; Jackson A; Dickinson L; Else L; Barber T; Mora-Peris B; Back D; Boffito M; Winston A
HIV Clin Trials; 2015; 16(1):39-42. PubMed ID: 25777188
[TBL] [Abstract][Full Text] [Related]
36. Brief Report: Surveillance of Congenital Anomalies After Exposure to Raltegravir or Elvitegravir During Pregnancy in the United Kingdom and Ireland, 2008-2018.
Rasi V; Cortina-Borja M; Peters H; Sconza R; Thorne C
J Acquir Immune Defic Syndr; 2019 Mar; 80(3):264-268. PubMed ID: 30531300
[TBL] [Abstract][Full Text] [Related]
37. Rapid reduction in HIV viral load in late pregnancy with raltegravir: a case report.
Cha A; Shaikh R; Williams S; Berkowitz LL
J Int Assoc Provid AIDS Care; 2013; 12(5):312-4. PubMed ID: 23695227
[TBL] [Abstract][Full Text] [Related]
38. Validation of an electrospray ionization LC-MS/MS method for quantitative analysis of raltegravir, etravirine, and 9 other antiretroviral agents in human plasma samples.
Quaranta S; Woloch C; Paccou A; Giocanti M; Solas C; Lacarelle B
Ther Drug Monit; 2009 Dec; 31(6):695-702. PubMed ID: 19865000
[TBL] [Abstract][Full Text] [Related]
39. Simultaneous measurement of etravirine, maraviroc and raltegravir in pigtail macaque plasma, vaginal secretions and vaginal tissue using a LC-MS/MS assay.
Blakney AK; Jiang Y; Whittington D; Woodrow KA
J Chromatogr B Analyt Technol Biomed Life Sci; 2016 Jul; 1025():110-8. PubMed ID: 27236000
[TBL] [Abstract][Full Text] [Related]
40. [Antiretroviral therapy containing raltegravir in HIV-infected pregnant women: Systematic review].
García-Fernández L; Fiestas F; Vásquez R; Benites C
Rev Chilena Infectol; 2016 Oct; 33(Suppl 1):60-66. PubMed ID: 28453028
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
